{"id":"antazoline","rwe":[{"pmid":"41189991","year":"2025","title":"Usability of CHA(2)DS(2)VASC score in predicting the effectiveness and safety of pharmacological cardioversion - data from the multicenter cardioversion with intravenous ANTazoline study.","finding":"","journal":"Frontiers in cardiovascular medicine","studyType":"Clinical Study"},{"pmid":"39929449","year":"2025","title":"Corrigendum to \"Effectiveness of antazoline versus amiodarone, flecainide and propafenone in restoring sinus rhythm at the emergency department\" [Adv. Med. Sci (2024 Sep) 69(2) 248-255].","finding":"","journal":"Advances in medical sciences","studyType":"Clinical Study"},{"pmid":"39743918","year":"2025","title":"Time efficiency and safety of antazoline in the rapid cardioversion of recent onset atrial fibrillation during supraventricular arrhythmias ablation.","finding":"","journal":"Kardiologia polska","studyType":"Clinical Study"},{"pmid":"38828867","year":"2024","title":"External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis.","finding":"","journal":"The Cochrane database of systematic reviews","studyType":"Clinical Study"},{"pmid":"38771221","year":"2024","title":"Effectiveness of antazoline versus amiodarone, flecainide, and propafenone in restoring sinus rhythm at the Emergency Department - case-match study.","finding":"","journal":"Cardiology journal","studyType":"Clinical Study"}],"tags":[{"label":"antazoline","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Histamine H1 receptor","category":"target"},{"label":"HRH1","category":"gene"},{"label":"R01AC04","category":"atc"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Active","category":"status"},{"label":"Allergic conjunctivitis","category":"indication"},{"label":"Allergic rhinitis","category":"indication"},{"label":"Anaphylaxis Adjunct","category":"indication"},{"label":"Dermatographic urticaria","category":"indication"},{"label":"Itching of skin","category":"indication"},{"label":"Nasal congestion","category":"indication"},{"label":"Novartis","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Anti-Allergic Agents","category":"pharmacology"},{"label":"Histamine Agents","category":"pharmacology"},{"label":"Histamine Antagonists","category":"pharmacology"},{"label":"Histamine H1 Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"marketed","safety":{"commonSideEffects":[],"contraindications":["Angle-closure glaucoma","Benign prostatic hyperplasia","Bladder outflow obstruction","Chronic idiopathic constipation","Diabetes mellitus","Disorder of cardiovascular system","Eye infection","Hyperglycemia","Hypertensive disorder","Hyperthyroidism","Injury of eye region","Ocular hypertension","Peptic ulcer","Retention of urine"]},"trials":[],"aliases":[],"company":"Novartis","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ANTAZOLINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:20:59.775124+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:21:05.440596+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ANTAZOLINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:21:05.733872+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1305/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:21:06.443464+00:00"}},"allNames":"phenazoline","offLabel":[],"synonyms":["antazoline mesylate","antazoline sulfate","antazoline","phenazoline","antazoline phosphate","antazoline hydrochloride","antazoline HCl"],"timeline":[{"date":"1990-04-30","type":"positive","source":"DrugCentral","milestone":"FDA approval (Novartis)"}],"brandName":"Phenazoline","ecosystem":[{"indication":"Allergic conjunctivitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alcaftadine","slug":"alcaftadine","company":"Allergan"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"astemizole","slug":"astemizole","company":""},{"name":"azatadine","slug":"azatadine","company":""}],"globalPrevalence":null},{"indication":"Anaphylaxis Adjunct","otherDrugs":[{"name":"azatadine","slug":"azatadine","company":""},{"name":"clemastine","slug":"clemastine","company":""},{"name":"diphenylpyraline","slug":"diphenylpyraline","company":"Glaxosmithkline"},{"name":"pheniramine","slug":"pheniramine","company":"Alcon"}],"globalPrevalence":null},{"indication":"Dermatographic urticaria","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"azatadine","slug":"azatadine","company":""},{"name":"brompheniramine","slug":"brompheniramine","company":""},{"name":"carbinoxamine","slug":"carbinoxamine","company":"Mcneil"}],"globalPrevalence":68000000},{"indication":"Itching of skin","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"allantoin","slug":"allantoin","company":""},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"azatadine","slug":"azatadine","company":""}],"globalPrevalence":null},{"indication":"Nasal congestion","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"azatadine","slug":"azatadine","company":""}],"globalPrevalence":null},{"indication":"Nasal discharge","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"azatadine","slug":"azatadine","company":""}],"globalPrevalence":30000000},{"indication":"Ocular Itching","otherDrugs":[{"name":"epinastine","slug":"epinastine","company":"Allergan"},{"name":"naphazoline","slug":"naphazoline","company":"Novartis"},{"name":"nedocromil","slug":"nedocromil","company":"King Pharms"},{"name":"pheniramine","slug":"pheniramine","company":"Alcon"}],"globalPrevalence":null}],"mechanism":{"target":"Histamine H1 receptor","novelty":"Follow-on","targets":[{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"}],"modality":"Small Molecule","drugClass":"antazoline","explanation":"","oneSentence":"","technicalDetail":"Phenazoline competitively binds to the histamine H1 receptor, inhibiting the action of histamine and reducing the symptoms associated with allergic reactions."},"commercial":{"launchDate":"1990","_launchSource":"DrugCentral (FDA 1990-04-30, NOVARTIS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/224","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ANTAZOLINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ANTAZOLINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:48:55.622368","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:21:08.063374+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"cromoglicic acid","drugSlug":"cromoglicic-acid","fdaApproval":"1982-05-28","relationship":"same-class"},{"drugName":"levocabastine","drugSlug":"levocabastine","fdaApproval":"1993-11-10","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"azelastine","drugSlug":"azelastine","fdaApproval":"1996-11-01","patentExpiry":"Jun 4, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nedocromil","drugSlug":"nedocromil","fdaApproval":"1992-12-30","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"olopatadine","drugSlug":"olopatadine","fdaApproval":"1996-12-18","patentExpiry":"May 19, 2032","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"antazoline","indications":{"approved":[{"name":"Allergic conjunctivitis","source":"DrugCentral","snomedId":473460002,"regulator":"FDA","eligibility":"No information available"},{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA","eligibility":"No information available"},{"name":"Anaphylaxis Adjunct","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No information available"},{"name":"Dermatographic urticaria","source":"DrugCentral","snomedId":7632005,"regulator":"FDA","eligibility":"No information available","usPrevalence":null,"globalPrevalence":68000000,"prevalenceMethod":"curated","prevalenceSource":"Allergy, 2020 (PMID:31494963)"},{"name":"Itching of skin","source":"DrugCentral","snomedId":418363000,"regulator":"FDA","eligibility":"No information available"},{"name":"Nasal congestion","source":"DrugCentral","snomedId":68235000,"regulator":"FDA","eligibility":"No information available"},{"name":"Nasal discharge","source":"DrugCentral","snomedId":64531003,"regulator":"FDA","eligibility":"No information available","usPrevalence":null,"globalPrevalence":30000000,"prevalenceMethod":"curated","prevalenceSource":"Influenza Other Respir Viruses, 2023 (PMID:36824394)"},{"name":"Ocular Itching","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No information available"},{"name":"Red eye","source":"DrugCentral","snomedId":75705005,"regulator":"FDA","eligibility":"No information available"},{"name":"Sneezing","source":"DrugCentral","snomedId":76067001,"regulator":"FDA","eligibility":"No information available"},{"name":"Urticaria","source":"DrugCentral","snomedId":126485001,"regulator":"FDA","usPrevalence":null,"globalPrevalence":68000000,"prevalenceMethod":"curated","prevalenceSource":"Allergy, 2020 (PMID:31494963)"},{"name":"Vasomotor rhinitis","source":"DrugCentral","snomedId":8229003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cromoglicic-acid","brandName":"cromoglicic acid","genericName":"cromoglicic acid","approvalYear":"1982","relationship":"same-class"},{"drugId":"levocabastine","brandName":"levocabastine","genericName":"levocabastine","approvalYear":"1993","relationship":"same-class"},{"drugId":"azelastine","brandName":"azelastine","genericName":"azelastine","approvalYear":"1996","relationship":"same-class"},{"drugId":"nedocromil","brandName":"nedocromil","genericName":"nedocromil","approvalYear":"1992","relationship":"same-class"},{"drugId":"olopatadine","brandName":"olopatadine","genericName":"olopatadine","approvalYear":"1996","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05720572","phase":"PHASE4","title":"Antazoline in Comparison to Propafenone in Pharmacological Cardioversion of Atrial Fibrillation.","status":"UNKNOWN","sponsor":"Centre of Postgraduate Medical Education","startDate":"2019-09-01","conditions":["Atrial Fibrillation"],"enrollment":105,"completionDate":"2026-01-01"},{"nctId":"NCT01527279","phase":"PHASE4","title":"Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation","status":"COMPLETED","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2012-11","conditions":["Paroxysmal Atrial Fibrillation"],"enrollment":74,"completionDate":"2015-03"},{"nctId":"NCT01380678","phase":"PHASE3","title":"Intralesional Bevacizumab Injection on Primary Pterygium","status":"UNKNOWN","sponsor":"Khon Kaen University","startDate":"2009-01","conditions":["Pterygium","Inflammation"],"enrollment":206,"completionDate":"2012-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule","formulations":[{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"Nestabs ONE"}]},"crossReferences":{"NUI":"N0000147709","MMSL":"4205","NDDF":"003378","UNII":"DHA8014SS1","VUID":"4019615","CHEBI":"CHEBI:84115","VANDF":"4019060","INN_ID":"1142","RXNORM":"81954","UMLSCUI":"C0003143","chemblId":"CHEMBL1305","ChEMBL_ID":"CHEMBL1305","KEGG_DRUG":"D02950","DRUGBANK_ID":"DB08799","PUBCHEM_CID":"2200","SNOMEDCT_US":"373544004","IUPHAR_LIGAND_ID":"7116","SECONDARY_CAS_RN":"3131-32-6","MESH_DESCRIPTOR_UI":"D000865"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1990-","companyName":"Novartis","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.29 hours","clearance":"19.67 mL/min/kg","volumeOfDistribution":"3.9 L/kg"},"publicationCount":230,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"R01AC04","allCodes":["R01AC04","R06AX05"]},"biosimilarFilings":[],"originalDeveloper":"Novartis","recentPublications":[{"date":"2025","pmid":"41189991","title":"Usability of CHA(2)DS(2)VASC score in predicting the effectiveness and safety of pharmacological cardioversion - data from the multicenter cardioversion with intravenous ANTazoline study.","journal":"Frontiers in cardiovascular medicine"},{"date":"2025 Mar","pmid":"39929449","title":"Corrigendum to \"Effectiveness of antazoline versus amiodarone, flecainide and propafenone in restoring sinus rhythm at the emergency department\" [Adv. Med. Sci (2024 Sep) 69(2) 248-255].","journal":"Advances in medical sciences"},{"date":"2025","pmid":"39743918","title":"Time efficiency and safety of antazoline in the rapid cardioversion of recent onset atrial fibrillation during supraventricular arrhythmias ablation.","journal":"Kardiologia polska"},{"date":"2024 Jun 3","pmid":"38828867","title":"External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis.","journal":"The Cochrane database of systematic reviews"},{"date":"2024","pmid":"38771221","title":"Effectiveness of antazoline versus amiodarone, flecainide, and propafenone in restoring sinus rhythm at the Emergency Department - case-match study.","journal":"Cardiology journal"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"1990","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:21:08.063374+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}